SOLANA BEACH, Calif. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will release financial results for the fourth quarter and full year ended
SOLANA BEACH Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration ( FDA ) in association with the Gimoti 505(b)(2) New Drug Application (NDA).
Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration ( FDA ) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1 , 2019 Prescription Drug User Fee Act (PDUFA) date maintained Company expects to hold a conference call at a later date instead of its
Meeting with FDA scheduled for March 21, 2019 SOLANA BEACH, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S.
SOLANA BEACH, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S.
Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter
SOLANA BEACH, Calif. , June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S.
NDA resubmission anticipated in fourth quarter 2019 SOLANA BEACH, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that following receipt of U.S.
SOLANA BEACH, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches of its product candidate Gimoti
Gimoti NDA resubmission on track for fourth quarter 2019 SOLANA BEACH, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third
